Skip to main content
SpringerLink
Log in

HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?

  • Chapter
  • First Online:
Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond

Abstract

The introduction of cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy has greatly improved the prognosis of patients with peritoneal carcinomatosis in both phase II and III trials. A clear pharmacologic and clinical rationale for this treatment strategy has been demonstrated. Whereas the cytoreductive surgery has been highly standardized, reproducible, and predictable, the same cannot be said of the intraperitoneal chemotherapy modalities. A staggering variety of chemotherapy application techniques and regimens has been reported. Most of these regimens have been based on extrapolation of systemic chemotherapy data. An urgent need for more standardization of the intraperitoneal chemotherapy modalities is needed. The aim of this manuscript is to review the rationale, variables, and modalities of intraperitoneal chemotherapy. At the same time, it seeks to offer guidance on the current intraperitoneal chemotherapy regimens and potential directions toward more standardization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

5-FU:

5-Fluorouracil

AUC:

  Area under the curve

BIC:

Bidirectional intraoperative chemotherapy

BSA:

Body surface area

CRS:

Cytoreductive surgery

EPIC:

Early postoperative intraperitoneal chemotherapy

HIPEC:

Hyperthermic intraperitoneal peroperative chemotherapy

IP:

Intraperitoneal

IV:

Intravenous

MTC:

Mass transfer coefficient

NIPS:

Neoadjuvant intraperitoneal and systemic chemotherapy

PIPAC:

Pressurized intraperitoneal aerosol chemotherapy

PM:

Peritoneal metastases

SPIC:

Sequenced postoperative intraperitoneal chemotherapy

References

  1. Sheperd NA, Baxter KJ, Sharon BL. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology. 1997;112(4):1096–102.

    Article  Google Scholar 

  2. Yang SH, Lin JK, Lai CR, Chen CC, Li AF, Liang WY, et al. Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol. 2004;87(4):167–73.

    Article  PubMed  Google Scholar 

  3. Noura S, Ohue M, Seki Y, Yano M, Ishikawa O, Kameyama M. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum. 2009;52(7):1312–20.

    Article  PubMed  Google Scholar 

  4. Ribeiro U Jr, Safatle-Ribeiro AV, Zilberstein B, Mucerino D, Yagi OK, Bresciani CC, et al. Does the intraoperative peritoneal lavage cytology add prognostic information in patients with potentially curative gastric resection? J Gastrointest Surg. 2006;10(2):170–6.

    Article  PubMed  Google Scholar 

  5. Yamamoto S, Akasu T, Fujita S, Moriya Y. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol. 2003;33(1):33–7.

    Article  PubMed  Google Scholar 

  6. Lennon AM, Mulcahy HE, Hyland J, Lowry C, White A, Fennelly D, et al. Peritoneal involvement is a powerful prognostic indicator in stage II colonic cancer. Gastroenterology. 2002;122S(4):A41.

    Google Scholar 

  7. Hase K, Ueno H, Kuranaga N, Utsonomiya K, Kanabe S, Mochizuki H. Intraperitoneal exfoliated cancer cells in patients with colorectal cancer. Dis Colon Rectum. 1998;41(9):1134–40.

    Article  CAS  PubMed  Google Scholar 

  8. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg. 1995;130(4):387–93.

    Article  CAS  PubMed  Google Scholar 

  9. Rosenshein NB, Leichner PK, Vogelsang G. Radiocolloids in the treatment of ovarian cancer. Obstet Gynecol. 1979;34(9):708–20.

    CAS  Google Scholar 

  10. Meyers MA. The spread and localization of acute intraperitoneal effusions. Radiology. 1970;95(3):547–54.

    Article  CAS  PubMed  Google Scholar 

  11. Meyers MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Therapy, Nucl Med. 1973;119(1):198–206.

    Article  CAS  Google Scholar 

  12. Carmignani PC, Tessa AS, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patters of spread. Cancer Metastasis Rev. 2003;22(4):465–72.

    Article  PubMed  Google Scholar 

  13. Patel H, Le Marer N, Wharton RQ, Khan ZA, Araia R, Glover C, et al. Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann Surg. 2002;235(2):226–31.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tanida O, Kaneshima S, Iitsuka Y, Kuda H, Kiyasu Y, Koga S. Viability of intraperitoneal free cancer cells in patients with gastric cancer. Acta Cytol. 1982;26(5):681–7.

    CAS  PubMed  Google Scholar 

  15. Sugarbaker PH. Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Investig. 2005;23(2):155–72.

    Article  Google Scholar 

  16. Kodera Y, Nakanishi H, Ito S, Yamamura Y, Kanemitsu Y, Shimizu Y, et al. Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg. 2002;235(4):499–506.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ceelen WP, Morris S, Paraskeva P, Pattyn P. Surgical trauma, minimal residual diseaese and locoregional cancer recurrence. Cancer Treat Res. 2007;134:51–69.

    CAS  PubMed  Google Scholar 

  18. van der Bij GJ, Oosterling SJ, Beelen RH, Meijer S, Coffey JC, van Egmond M. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 2009;249(5):727–34.

    Article  PubMed  Google Scholar 

  19. Oosterling SJ, van der Bij GJ, van Egmond M, van der Sijp JR. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur J Surg Oncol. 2005;31(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  20. Jayne D. Molecular biology of peritoneal carcinomatosis. Cancer Treat Res. 2007;134:21–33.

    CAS  PubMed  Google Scholar 

  21. Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention and treatment. Lancet Oncol. 2009;10(1):72–9.

    Article  PubMed  Google Scholar 

  22. Spratt JD, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256–60.

    CAS  PubMed  Google Scholar 

  23. Koga S, Shimizu N, Maeta M, Hamazoe R, Izumi A. Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system). Gan To Kagaku Ryoho. 1983;10(2pt2):358–65.

    CAS  PubMed  Google Scholar 

  24. Speyer JL, Myers CE. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res. 1980;74:264–9.

    Article  CAS  PubMed  Google Scholar 

  25. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12(3):703–27.

    Article  PubMed  Google Scholar 

  26. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267–72.

    Article  CAS  PubMed  Google Scholar 

  27. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.

    Article  PubMed  Google Scholar 

  28. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.

    Article  PubMed  Google Scholar 

  29. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.

    Article  CAS  PubMed  Google Scholar 

  30. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24(24):4011–9.

    Article  PubMed  Google Scholar 

  31. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy from pseudomyxoma peritonei. Ann Surg Oncol. 2007;14(2):484–92.

    Article  PubMed  Google Scholar 

  32. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827–34.

    Article  CAS  PubMed  Google Scholar 

  33. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.

    Article  PubMed  Google Scholar 

  34. Yan TD, Deraco M, Baratti D, Kusumura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.

    Article  PubMed  Google Scholar 

  35. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18(12):1943–50.

    Article  CAS  PubMed  Google Scholar 

  36. Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010;20(1):61–9.

    Article  PubMed  Google Scholar 

  37. Elias D, Glehen O, Gilly F. Carcinose péritonéles d’origine digestive et primitive. Rapport du 110éme congrès de l’AFC. France: Arnette: Wolters Kluwer; 2008.

    Google Scholar 

  38. Glehen O, Gilly FN, Arvieux C, Cotte C, Boutitie F, Mansveldt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7. [Epub ahead of print].

    Article  PubMed  Google Scholar 

  39. Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251(5):896–901.

    Article  PubMed  Google Scholar 

  40. Baron MA. Structure of the intestinal peritoneum in man. Am J Anat. 1941;69:439–97.

    Article  Google Scholar 

  41. Dobbie JW. Ultrastructure and pathology of the peritoneal dialysis. In: Gokal R, Nolph K, editors. Textbook of peritoneal dialysis. Dordrecht: Kluwer Academic; 1994. p. 17–45.

    Chapter  Google Scholar 

  42. Mutsaers SE, Wilkosz S. Structure and function of mesothelial cells. Cancer Treat Res. 2007;134:1–19.

    CAS  PubMed  Google Scholar 

  43. Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93–6.

    Article  PubMed  Google Scholar 

  44. Flessner M, Henegar J, Bigler S, Genous L. Is the peritoneum a significant barrier in peritoneal dialysis? Perit Dial Int. 2003;23(6):542–9.

    CAS  PubMed  Google Scholar 

  45. de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52(2):108–12.

    Article  PubMed  CAS  Google Scholar 

  46. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55(2):130–8.

    Article  CAS  PubMed  Google Scholar 

  47. Stelin G, Rippe BA. Phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int. 1990;38(3):456–72.

    Article  Google Scholar 

  48. Bettendorf U. Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics. Lymphology. 1978;11(3):111–6.

    CAS  PubMed  Google Scholar 

  49. Bettendorf U. Electronmicroscopic studies on the peritoneal resorption of intraperitoneally injected latex particles via the diaphragmatic lymphatics. Lymphology. 1979;12(2):66–70.

    CAS  PubMed  Google Scholar 

  50. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12(3):673–88.

    Article  PubMed  Google Scholar 

  51. Dedrick RL, Myers CE, Bungay PM, De Vita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.

    CAS  PubMed  Google Scholar 

  52. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Phys. 1985;248(3 Pt 2):F425–35.

    CAS  Google Scholar 

  53. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12(3 Suppl 4):1–6.

    CAS  PubMed  Google Scholar 

  54. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288(3):F433–42.

    Article  CAS  PubMed  Google Scholar 

  55. Flessner MF. Intraperitoneal drug therapy: physical and biological principles. Cancer Treat Res. 2007;134:131–52.

    CAS  PubMed  Google Scholar 

  56. Zylberberg B, Dormont D, Janklewicz S, Darai E, Bretel JJ, Poncelet C, et al. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol. 2001;22:40–5.

    CAS  PubMed  Google Scholar 

  57. Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2016;24(2):478–85.

    Article  PubMed  Google Scholar 

  58. Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:8.

    Google Scholar 

  59. Esquivel J, Vidal-Jove J, Steves M, Sugarbaker P. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993;113:631–6.

    CAS  PubMed  Google Scholar 

  60. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

    Article  CAS  PubMed  Google Scholar 

  61. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an inter-group study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–7.

    Article  CAS  PubMed  Google Scholar 

  62. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950–5.

    Article  CAS  PubMed  Google Scholar 

  63. Gardner SN. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and – non-specific drugs. Cancer Res. 2000;60(5):1417–25.

    CAS  PubMed  Google Scholar 

  64. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemothera-py. Surg Oncol Clin N Am. 2003;12(3):813–24.

    Article  PubMed  Google Scholar 

  65. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on the pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2001;47(3):269–76.

    Article  CAS  PubMed  Google Scholar 

  66. Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52(5):405–10.

    Article  CAS  PubMed  Google Scholar 

  67. Kondo A, Maeta M, Oka A, Tsujitani S, Ikeguchi M, Kaibara N. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer. 1996;73(10):1166–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Tsujitani S, Oka A, Kondo A, Katano K, Oka S, Saito H, et al. Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cispla-tin chemotherapy for peritoneal carcinomatosis in rats. Oncology. 1999;57(1):77–82.

    Article  CAS  PubMed  Google Scholar 

  69. Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, et al. Hu-man pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology. 2002;63(4):346–52.

    Article  CAS  PubMed  Google Scholar 

  70. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89(7):480–7.

    Article  CAS  PubMed  Google Scholar 

  71. Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ysna MD, et al. High intraabdominal pressure enhances the penetration and antitumor effect of intra-peritoneal cisplatin on experimental carcinomatosis. Ann Surg. 2006;244(1):106–12.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effect of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intra-peritoneal administration. Anti-Cancer Drugs. 1996;7(5):596–603.

    Article  CAS  PubMed  Google Scholar 

  73. Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 2008;15(1):339–44.

    Article  PubMed  Google Scholar 

  74. Thomas F, Ferron G, Gesson-Paute A, Hristova M, Lochon I, Chatelut E. Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15(12):3623–4.

    Article  PubMed  Google Scholar 

  75. Garofalo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 2006;32(6):682–5.

    Article  CAS  PubMed  Google Scholar 

  76. Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional analysis in 52 patients. J Surg Oncol. 2009;100(4):331–4.

    Article  CAS  PubMed  Google Scholar 

  77. Facchiano E, Scaringi S, Kianmanesh R, Sabate JM, Castel B, Flamant Y, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomato-sis from advanced gastric cancer. Eur J Surg Oncol. 2008;34(2):154–8.

    Article  CAS  PubMed  Google Scholar 

  78. Patriti A, Cavazzoni E, Graziosi L, Pisciaroli A, Luzi D, Gullà N, et al. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech. 2008;18(4):426–8.

    Article  PubMed  Google Scholar 

  79. Tempfer CB. Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis. Med Hypotheses. 2015;85(4):480–4.

    Article  PubMed  Google Scholar 

  80. Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26(7):1849–55.

    Article  PubMed  Google Scholar 

  81. Solass W, Herbette A, Schwarz T, Hetzel A, Sun JS, Dutreix M, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26(3):847–52.

    Article  PubMed  Google Scholar 

  82. Solass W, Kerb R, Murdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9.

    Article  PubMed  Google Scholar 

  83. Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20(11):3504–11.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol. 2015;137(2):223–8.

    Article  CAS  PubMed  Google Scholar 

  85. Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311–6.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14(1):128.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Forster E, Zieren J, Giger-Pabst U. Exploring the spatial drug distribution pattern of pressurized Intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2016;23(4):1220–4.

    Article  PubMed  Google Scholar 

  88. Demtroder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Color Dis. 2016;18(4):364–71.

    Article  CAS  Google Scholar 

  89. Tempfer CB, Solass W, Buerkle B, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: a case report. Gynecol Oncol Rep. 2014;10:32–5.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Kakchekeeva T, Demtroder C, Herath NI, Griffiths D, Torkington J, Solass W, et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol. 2016;23(Suppl 5):592–8.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.

    Article  PubMed  Google Scholar 

  92. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth. 2007;23:431–42.

    Article  CAS  Google Scholar 

  93. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41:147–54.

    Article  CAS  PubMed  Google Scholar 

  94. Young JS, Lumsden CE, Stalker AL. The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol. 1950;62:313–33.

    Article  CAS  PubMed  Google Scholar 

  95. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, Messmer K. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992;52:487–90.

    CAS  PubMed  Google Scholar 

  96. Sugarbaker PSO, Bijelic L, et al. Hyperthermic intraperitoneal gemcitabine chemotherapy for patients with resected pancreatic cancer: clinical pharmacologic data. Curr Top Pharmacol. 2014;18:81–92.

    CAS  Google Scholar 

  97. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperth. 1999;15:79–107.

    Article  CAS  Google Scholar 

  98. Sugarbaker PH. Parietal peritonectomy. Ann Surg Oncol. 2012;19:1250.

    Article  PubMed  Google Scholar 

  99. Konate A, Poupon J, Villa A, Garnier R, Hasni-Pichard H, Mezzaroba D, Fernandez G, Pocard M. Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. J Surg Oncol. 2011;103:6–9.

    Article  PubMed  Google Scholar 

  100. Schenk KE, Schierl R, Angele M, Burkhart-Reichl A, Glockzin G, Novotny A, Nowak D. Cisplatin and oxaliplatin surface contamination in intensive care units (ICUs) and hospital wards during attendance of HIPEC patients. Int Arch Occup Environ Health. 2016;89(6):991–6.

    Article  CAS  PubMed  Google Scholar 

  101. Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, Elias D, Joly N, Payen D, Blot F, Poupon J, Garnier R. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health. 2015;53:28–37.

    Article  CAS  PubMed  Google Scholar 

  102. Capron A, Destree J, Jacobs P, Wallemacq P. Permeability of gloves to selected chemotherapeutic agents after treatment with alcohol or isopropyl alcohol. Am J Health Syst Pharm. 2012;69:1665–1670. [PMID: 22997120. https://doi.org/10.2146/ajhp110733.

    Article  CAS  PubMed  Google Scholar 

  103. Ferron G, Simon L, Guyon F, Glehen O, Goere D, Elias D, Pocard M, Gladieff L, Bereder JM, Brigand C, Classe JM, Guilloit JM, Quenet F, Abboud K, Arvieux C, Bibeau F, De Chaisemartin C, Delroeux D, Durand-Fontanier S, Goasguen N, Gouthi L, Heyd B, Kianmanesh R, Leblanc E, Loi V, Lorimier G, Marchal F, Mariani P, Mariette C, Meeus P, Msika S, Ortega-Deballon P, Paineau J, Pezet D, Piessen G, Pirro N, Pomel C, Porcheron J, Pourcher G, Rat P, Regimbeau JM, Sabbagh C, Thibaudeau E, Torrent JJ, Tougeron D, Tuech JJ, Zinzindohoue F, Lundberg P, Herin F, Villeneuve L, BIG-RENAPE Working Group. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): a French multicentric survey. Eur J Surg Oncol. 2015;41:1361–7.

    Article  CAS  PubMed  Google Scholar 

  104. Boutros C, Somasundar P, Espat NJ. Early results on the use of biomaterials as adjuvant to abdominal wall closure following cytoreduction and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2010;8:72.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.

    Article  CAS  PubMed  Google Scholar 

  106. Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.

    Article  PubMed  Google Scholar 

  107. Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, Chauffert B, Rat P. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol. 2010;17:1957–63.

    Article  PubMed  Google Scholar 

  108. Facy O, Combier C, Poussier M, Magnin G, Ladoire S, Ghiringhelli F, Chauffert B, Rat P, Ortega-Deballon P. High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery. 2015;157:72–8.

    Article  PubMed  Google Scholar 

  109. Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431–9.

    CAS  PubMed  Google Scholar 

  110. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–6.

    Article  CAS  PubMed  Google Scholar 

  111. Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A, Efstathiou E, Spiliotis J. Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol. 2015;2015:6.

    Google Scholar 

  112. Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer. 1990;65:65–71.

    Article  CAS  PubMed  Google Scholar 

  113. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am. 2003;12:635–48.

    Article  PubMed  Google Scholar 

  114. Hirose K, Katayama K, Iida A, Yamaguchi A, Nakagawara G, Umeda S, Kusaka Y. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology. 1999;57:106–14.

    Article  CAS  PubMed  Google Scholar 

  115. Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15:542–6.

    Article  PubMed  Google Scholar 

  116. Rat P, Benoit L, Cheynel N, Osmak L, Favoulet P, Peschaud F, Chauffert B, Favre JP. Intraperitoneal chemo-hyperthermia with “overflow” open abdomen. Ann Chir. 2001;126:669–71.

    Article  CAS  PubMed  Google Scholar 

  117. Froysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016;114(2):222–7.

    Article  PubMed  Google Scholar 

  118. Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990;50(18):5790–4.

    CAS  PubMed  Google Scholar 

  119. Mahteme H, von Heideman A, Grundmark B, Tholander B, Pahlman L, Glimelius B, et al. Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. Eur J Surg Oncol. 2008;34(5):547–52.

    Article  CAS  PubMed  Google Scholar 

  120. Cashin PH, Mahteme H, Graf W, Karlsson H, Larsson R, Nygren P. Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer. BMC Cancer. 2013;13:435.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  121. Levine EA, Blazer DG, Kim MK, Shen P, Stewart JH, Guy C, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg. 2012;214(4):599–606. discussion -7.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Fujishima Y, Goi T, Kimura Y, Hirono Y, Katayama K, Yamaguchi A. MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer. Int J Oncol. 2012;40(4):960–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Stewart JH, Shen P, Russell G, Fenstermaker J, McWilliams L, Coldrun FM, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15(8):2137–45.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Elias D, Raynard B, Bonnay M, Pocard M. Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol. 2006;32(6):607–13.

    Article  CAS  PubMed  Google Scholar 

  125. Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol. 2010;36(6):589–93.

    Article  CAS  PubMed  Google Scholar 

  126. Chalret du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol. 2014;74(3):571–82.

    Article  CAS  PubMed  Google Scholar 

  127. Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quenet F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23(7):2315–22.

    Article  PubMed  Google Scholar 

  128. De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28(1):61–6.

    PubMed  Google Scholar 

  129. Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004;21(5):891–4.

    Article  CAS  PubMed  Google Scholar 

  130. Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015;479(1):23–7.

    Article  CAS  PubMed  Google Scholar 

  131. Fujita T, Tamura T, Yamada H, Yamamoto A, Muranishi S. Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. J Drug Target. 1997;4(5):289–96.

    Article  CAS  PubMed  Google Scholar 

  132. Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2011;68(1):147–56.

    Article  CAS  PubMed  Google Scholar 

  133. Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18(2):e84–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573–85.

    Article  PubMed  Google Scholar 

  135. de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res. 2007;169:53–73

    Google Scholar 

  136. Witkamp A. Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin. Eur J Surg Oncol. 1998;24:18.

    Google Scholar 

  137. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from the American Society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–5.

    Article  CAS  PubMed  Google Scholar 

  138. Rubin J, Clawson M, Planch A, Jones Q. Measurements of peritoneal surface area in man and rat. Am J Med Sci. 1988;295(5):453–8.

    Article  CAS  PubMed  Google Scholar 

  139. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am. 2003;12(3):755–69, xiv.

    Article  PubMed  Google Scholar 

  140. Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57(5):703–8.

    Article  CAS  PubMed  Google Scholar 

  141. Mas-Fuster MI, Ramon-Lopez A, Nalda-Molina R. Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view. Cancer Chemother Pharmacol. 2013;72(1):273–4.

    Article  PubMed  Google Scholar 

  142. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63–8. https://doi.org/10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Apr 1;28(10):1808.

    Article  PubMed  Google Scholar 

  143. Hompes D, D’Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109(6):527–32. https://doi.org/10.1002/jso.23546. Epub 2013 Dec 28.

    Article  CAS  PubMed  Google Scholar 

  144. Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R. The American Society of peritoneal surface malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Surg Oncol. 2014;110(7):779–85. https://doi.org/10.1002/jso.23728. Epub 2014 Aug 2.

    Article  CAS  Google Scholar 

  145. Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(1):144–9. https://doi.org/10.1016/j.ejso.2016.09.015. Epub 2016 Oct 13.

    Article  CAS  PubMed  Google Scholar 

  146. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49(12):3380–4.

    CAS  PubMed  Google Scholar 

  147. Conti M, De Giorgi U, Tazzari V, Bezzi F, Baccini C. Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. J Chemother. 2004;16(Suppl 5):23–5.

    Article  CAS  PubMed  Google Scholar 

  148. Gladieff L, Chatelut E, Dalenc F, Ferron G. Pharmacological bases of intraperitoneal chemotherapy. Bull Cancer. 2009;96(12):1235–42.

    CAS  PubMed  Google Scholar 

  149. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12–26.

    Article  CAS  PubMed  Google Scholar 

  150. Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al. HIPEC ROC I: a phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2014;136(3):699–708.

    PubMed  Google Scholar 

  151. Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36(10):1486–91.

    Article  CAS  PubMed  Google Scholar 

  152. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol. 2011;2011:9.

    Google Scholar 

  153. Deraco M, Baratti D, Cabras AD, Zaffaroni N, Perrone F, Villa R, et al. Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol. 2010;2(2):76–84.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Tritton TR. Cell surface actions of adriamycin. Pharmacol Ther. 1991;49(3):293–309.

    Article  CAS  PubMed  Google Scholar 

  155. Triton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science. 1982;217(4556):248–50.

    Article  CAS  PubMed  Google Scholar 

  156. Lane P, Vichi P, Bain DL, Tritton TR. Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Res. 1987;47(15):4038–42.

    CAS  PubMed  Google Scholar 

  157. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009;63(5):799–805.

    Article  PubMed  CAS  Google Scholar 

  158. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42(10):4265–9.

    CAS  PubMed  Google Scholar 

  159. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39(8):3209–14.

    CAS  PubMed  Google Scholar 

  160. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI, et al. Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. Cancer Treat Rep. 1979;63(2):269–73.

    CAS  PubMed  Google Scholar 

  161. Nagai K, Nogami S, Egusa H, Konishi H. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats. Pharmazie. 2014;69(2):125–7.

    CAS  PubMed  Google Scholar 

  162. Harrison LE, Bryan M, Pliner L, Saunders T. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol. 2008;15(5):1407–13.

    Article  PubMed  Google Scholar 

  163. Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, et al. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis. Drug Metab Dispos. 2012;40(12):2365–73.

    Article  CAS  PubMed  Google Scholar 

  164. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacology of perioperative 5-fluorouracil. J Surg Oncol. 2010;102(7):730–5.

    Article  PubMed  CAS  Google Scholar 

  165. Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2007;14(2):509–14.

    Article  PubMed  Google Scholar 

  166. McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol. 2013;107(6):591–6.

    Article  CAS  PubMed  Google Scholar 

  167. Tan GH, Ong WS, Chia CS, Tham CK, Soo KC, Teo MC. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? Int J Hyperth. 2016;32(3):281–8.

    Article  CAS  Google Scholar 

  168. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663–6.

    Article  CAS  PubMed  Google Scholar 

  169. Muggia FM, Peters GJ, Landolph JR Jr. XIII International Charles Heidelberger Symposium and 50 years of fluoropyrimidines in cancer therapy held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther. 2009;8(5):992–9.

    Article  CAS  PubMed  Google Scholar 

  170. Wagner PL, Jones D, Aronova A, Shia J, Weiser MR, Temple LK, et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis. Dis Colon Rectum. 2012;55(4):407–15.

    Article  PubMed  Google Scholar 

  171. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg. 2001;25(8):985–90.

    Article  CAS  PubMed  Google Scholar 

  172. Kwon OK, Chung HY, Yu W. Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat. 2014;46(3):270–9.

    Article  PubMed  PubMed Central  Google Scholar 

  173. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol. 2016;113(7):796–803.

    Article  PubMed  Google Scholar 

  174. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005;10(2):112–22.

    Article  CAS  PubMed  Google Scholar 

  175. Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Nat Prod Rep. 2014;31(3):335–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. de Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev. 2006;32(6):471–82.

    Article  PubMed  CAS  Google Scholar 

  177. Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am. 2003;12(3):825–33.

    Article  PubMed  Google Scholar 

  178. Van der Speeten K, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura and Peritoneum. 2017;2(2):63–72. Retrieved 28 Aug. 2017, from. https://doi.org/10.1515/pp-2017-0003.

    Google Scholar 

Download references

Acknowledgements

Lemoine L is supported by the Agency for Innovation by Science and Technology (IWT) in Brussels, Belgium. Lemoine L is a researcher for the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk (LSM), Hasselt University, Ziekenhuis Oost-Limburg, and Jessa Hospital, Belgium.

Conflict of Interest Statement

No potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Genk, Belgium

    K. Van der Speeten & L. Lemoine

  2. Department of Biochemistry, Faculty of Medicine, University Hasselt, Diepenbeek, Belgium

    K. Van der Speeten & L. Lemoine

  3. Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA

    K. Van der Speeten & L. Lemoine

Authors
  1. K. Van der Speeten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Lemoine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Van der Speeten .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, Fortis Hospital, Bangalore, India

    Aditi Bhatt

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Van der Speeten, K., Lemoine, L. (2018). HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?. In: Bhatt, A. (eds) Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond. Springer, Singapore. https://doi.org/10.1007/978-981-10-7053-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7053-2_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7052-5

  • Online ISBN: 978-981-10-7053-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation